Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Sea Limited
SE
|
$874M |
| 2 |
Coupang
CPNG
|
$809M |
| 3 |
Roblox
RBLX
|
$363M |
| 4 |
Analog Devices
ADI
|
$309M |
| 5 |
Adobe
ADBE
|
$255M |
Top Sells
| 1 |
Tesla
TSLA
|
$1.06B |
| 2 |
Petrobras
PBR
|
$460M |
| 3 |
Alibaba
BABA
|
$450M |
| 4 |
Zillow
Z
|
$381M |
| 5 |
NVIDIA
NVDA
|
$379M |
Sector Composition
| 1 | Consumer Discretionary | 28.1% |
| 2 | Healthcare | 23.85% |
| 3 | Technology | 19.62% |
| 4 | Communication Services | 11.36% |
| 5 | Financials | 5.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BZUN
226
Baozun
BZUN
$207M
| $12.7M | 0.01% |
1,479,159
-45,773
| -3% | -$393K |
|
|
BNFT
227
DELISTED
Benefitfocus, Inc.
BNFT
| $12.5M | 0.01% |
993,007
-20,168
| -2% | -$255K |
|
228
Visa
V
$666B
| $11.6M | 0.01% |
52,499
| – | – |
|
229
Bumble
BMBL
$697M
| $11.6M | 0.01% |
400,000
| – | – |
|
230
Health Catalyst
HCAT
$238M
| $11.5M | 0.01% |
440,167
+41,788
| +10% | +$1.09M |
|
231
American Superconductor
AMSC
$2.21B
| $11.3M | 0.01% |
1,491,370
| – | – |
|
232
Ascendis Pharma
ASND
$12.5B
| $11.1M | 0.01% |
94,651
+8,579
| +10% | +$1.01M |
|
233
Sherwin-Williams
SHW
$92.9B
| $11.1M | 0.01% |
44,453
| – | – |
|
234
Verisk Analytics
VRSK
$37.8B
| $10.8M | 0.01% |
50,495
| – | – |
|
235
Align Technology
ALGN
$10.1B
| $10.7M | 0.01% |
24,631
| – | – |
|
236
Butterfly Network
BFLY
$393M
| $10.5M | 0.01% |
2,215,630
+142,092
| +7% | +$676K |
|
|
NBTX
237
Nanobiotix
NBTX
$419M
| $10.5M | 0.01% |
1,400,000
| – | – |
|
|
HUYA
238
Huya Inc
HUYA
$796M
| $9.54M | 0.01% |
2,133,740
-5,519,408
| -72% | -$24.7M |
|
239
Veeva Systems
VEEV
$44.7B
| $9.49M | 0.01% |
44,655
+4,442
| +11% | +$944K |
|
240
Allbirds
BIRD
$51M
| $8.22M | 0.01% |
68,404
+41,779
| +157% | +$5.02M |
|
|
ZY
241
DELISTED
Zymergen Inc. Common Stock
ZY
| $8.16M | 0.01% |
2,821,956
| – | – |
|
|
API
242
Agora
API
$310M
| $7.4M | 0.01% |
744,300
| – | – |
|
243
Relay Therapeutics
RLAY
$710M
| $7.31M | 0.01% |
244,277
+19,236
| +9% | +$576K |
|
|
DCBO
244
Docebo
DCBO
$896M
| $7.23M | 0.01% |
139,764
+71
| +0.1% | +$3.67K |
|
245
HUTCHMED
HCM
$2.74B
| $6.92M | ﹤0.01% |
365,792
+1,724
| +0.5% | +$32.6K |
|
246
TJX Companies
TJX
$155B
| $6.51M | ﹤0.01% |
107,431
+20,538
| +24% | +$1.24M |
|
247
Fortive
FTV
$16.2B
| $5.96M | ﹤0.01% |
97,814
| – | – |
|
|
YSG
248
Yatsen Holding
YSG
$881M
| $5.66M | ﹤0.01% |
1,648,417
-3,514
| -0.2% | -$12.1K |
|
249
Alector
ALEC
$305M
| $5.59M | ﹤0.01% |
392,351
+32,627
| +9% | +$465K |
|
250
BridgeBio Pharma
BBIO
$10.2B
| $5.5M | ﹤0.01% |
541,891
+52,170
| +11% | +$530K |
|